Why Intellia Therapeutics Stock Is Rising Monday
Portfolio Pulse from Adam Eckert
Intellia Therapeutics' stock is rising after the company announced positive interim results from the Phase 1 study of NTLA-2002, a CRISPR-based treatment for hereditary angioedema (HAE). The treatment demonstrated a 95% mean reduction in monthly attack rate and a favorable safety profile. Ark Invest's Cathie Wood purchased Intellia shares last week for the ARKK and ARKG funds.
June 12, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intellia Therapeutics' stock is rising due to positive interim results from the Phase 1 study of NTLA-2002, a CRISPR-based treatment for hereditary angioedema (HAE).
The positive interim results from the Phase 1 study of NTLA-2002 indicate that the treatment is effective and safe, which is likely to boost investor confidence in Intellia Therapeutics. Additionally, the fact that Ark Invest's Cathie Wood purchased shares of the company last week further supports the positive outlook for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100